8-K: QT Imaging Holdings Faces Nasdaq Delisting Despite Promising Breast Imaging Technology

QT Imaging Holdings faces Nasdaq delisting but highlights its innovative breast imaging technology and partnerships.

Summary

• QT Imaging Holdings, Inc. (QTI) received notice from Nasdaq regarding delisting proceedings and suspension of trading, leading to trading on the OTCQB Venture Market under the symbol QTIH.
• The company posted an investor presentation on its website highlighting its QT Breast Scanner, which has FDA clearance as a transmission and reflection ultrasonic imaging system.
• QTI aims to improve medical imaging through software, machine learning, and smart physics, expanding market opportunities beyond traditional healthcare settings.
• The company has secured approximately $18 million in NIH funding for a new women's imaging solution.
• QTI's technology offers high-resolution, low-cost, radiation-free medical imaging, potentially improving diagnostic performance compared to mammograms and offering similar quality to MRI at a lower cost.
• The company has a distribution agreement with NXC Imaging (a subsidiary of Canon Medical Systems) for the U.S. market, with committed quarterly minimum order quantities for scanners through the end of 2026.
• QTI is also exploring opportunities in infant imaging and image-guided procedures, targeting multi-billion dollar markets.
• Clinical evidence suggests non-inferiority to Digital Breast Tomosynthesis (DBT) with higher specificity, particularly in dense breasts.
• QTI shipped six scanners in Q1 2025, generating $2.8 million in revenue with a 65% gross margin.
• The company closed a $10.1 million term loan to retire prior debt and provide working capital.
• QTI reiterated plans to deliver $18 million in revenue in 2025 (40 scanners) and $27 million in revenue in 2026 (60 scanners).
• The company reported a net loss of $11.1 million for Q1 2025, including significant non-cash expenses related to warrant and derivative liabilities, as well as debt modification and extinguishment expenses.
• Non-GAAP Adjusted EBITDA for Q1 2025 was $(0.9) million.
• QTI ended Q1 2025 with $3.0 million in cash.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company highlights its innovative technology and partnerships, the Nasdaq delisting and significant net loss raise concerns.

Positives

• The QT Breast Scanner has FDA clearance as a 3D imaging device.
• The technology offers a high-resolution, low-cost, radiation-free imaging solution.
• QTI has a distribution agreement with NXC Imaging, ensuring minimum order quantities.
• The company secured a $10.1 million term loan to improve its financial position.
• QTI is exploring new market opportunities, including infant imaging and image-guided procedures.
• QTI's technology has higher specificity compared to DBT, especially in dense breasts.
• QTI shipped six scanners and generated revenue of $2.8 Million with 65% gross margin in the first quarter of 2025.

Negatives

• QT Imaging received a delisting notice from Nasdaq.
• The company reported a net loss of $11.1 million for Q1 2025.
• The company has significant non-cash expenses related to warrant and derivative liabilities.
• Sensitivity is lower for QT (70.6%) compared to DBT (85.2%).

Risks

• The delisting from Nasdaq could negatively impact investor confidence and stock value.
• The company's reliance on NXC Imaging for distribution poses a risk if the partnership falters.
• The high net loss and significant non-cash expenses raise concerns about financial stability.
• The company's ability to achieve its revenue targets depends on successful commercial rollout and market adoption of its technology.
• The company's sensitivity is lower for QT (70.6%) compared to DBT (85.2%).

Future Outlook

QT Imaging plans to deliver $18 million in revenue in 2025 (shipment of 40 scanners) and $27 million in revenue in 2026 (shipment of 60 scanners), based on minimum order quantities from NXC Imaging.

Industry Context

The announcement comes amid increasing focus on breast density and the limitations of mammography, positioning QT Imaging's technology as a potential alternative or supplement to existing screening methods.

Comparison to Industry Standards

• The document compares QT Imaging's technology to mammography, DBT, MRI, and handheld ultrasound (HHUS).
• QT Imaging aims to offer similar image quality to MRI but at a lower cost and without radiation.
• The company claims its technology has higher specificity than DBT, particularly in dense breasts.
• The document highlights that other ultrasound products use 2D imaging for dense breast imaging, while QTI enhances specificity by taking advantage of the speed of sound information, which Is unavailable (or lower quality) with the competing technologies.

Stakeholder Impact

• Shareholders face potential losses due to the Nasdaq delisting.
• Employees may experience uncertainty due to the company's financial challenges.
• Customers could benefit from the innovative breast imaging technology.
• Suppliers may be affected by changes in production and distribution.

Next Steps

• Continue commercial rollout of QT Scanners through the distribution agreement with NXC Imaging.
• Pursue large-scale manufacturing with Canon Medical Systems.
• Expand into new markets, including infant imaging and image-guided procedures.
• Conduct further clinical trials to validate the technology's effectiveness.

Key Dates

Keywords

QT Imaging, Breast Imaging, Delisting, Nasdaq, QT Scanner, NXC Imaging, FDA Clearance, Medical Imaging, Ultrasound, Revenue